Abstract No. 3Indication: non-small cell lung cancer Clinical Trial: Clinical activity of the oral ALK inhibitor, PF-02341066, in ALK-positive patients with non-small cell lung cancer. Presentation Time: Sunday, June 6. ASCO Plenary Session. Notes: Pfizer gets a primetime slot at ASCO to highlight its research efforts into personalized cancer drugs.